In March 2026, the U.S. Food and Drug Administration (FDA) issued warning letters to more than 30 telehealth providers marketing compounded versions of semaglutide and tirzepatide for weight loss. The warning letters cite improper marketing claims, missing required disclosures, and in some cases, formulations that the FDA considers to be "essentially copies" of FDA-approved products — which is not permitted under federal compounding rules.
For patients currently using compounded GLP-1 medications, this enforcement action raises real questions about safety, legality, and continuity of care. This article walks through what changed, why, and what your options are.
Quick background: what is compounded semaglutide?
Compounded semaglutide is a non-FDA-approved version of the active ingredient in Ozempic and Wegovy, prepared by a licensed compounding pharmacy. It is typically sold at lower price points ($150-300/month) versus brand-name semaglutide ($1,000+/month retail).
Compounded medications exist in a legal carve-out: under section 503A of the Food, Drug, and Cosmetic Act, compounding pharmacies can produce non-FDA-approved formulations under specific conditions — most commonly to fill genuine clinical need that the FDA-approved version cannot meet.
What changed in 2025-2026
When the FDA placed semaglutide and tirzepatide on the official drug shortage list in 2022-2023, compounding pharmacies were permitted to produce compounded versions broadly. That ended in April 2025 (semaglutide) and March 2025 (tirzepatide) when the FDA declared the shortages resolved.
Compounding did not stop. Many pharmacies and telehealth providers continued, often by adding minor ingredients (e.g., vitamin B12, L-carnitine) to create "personalized" formulations they argue fall outside the "essentially a copy" prohibition. The FDA explicitly disagrees.
What the March 2026 warning letters say
The letters generally cite three categories of violations:
- Marketing compounded products as "the same as" FDA-approved medications